Suppression and augmentation of rat adjuvant arthritis with monoclonal anti-interferon-gamma antibody.
The effects of a monoclonal antibody (MoAb DB-1), which neutralized rat interferon-gamma (IFN-gamma), on the induction and progression of adjuvant arthritis in Lewis rats induced by intraplantar injection of Freund's complete adjuvant was studied. The animals were treated intraperitoneally with MoAb DB-1 (0.3-5 mg) for various times. Prophylactic treatment with MoAb DB-1, starting 2 days prior to arthritis induction, inhibited oedema in both the injected and non-injected hind paws and delayed joint destruction as shown by radiography. However, despite continued MoAb treatment, the disease progressed. High doses of MoAb DB-1 exacerbated the disease. A control MoAb of the same isotype did not have significant effects on adjuvant arthritis. Therapeutic treatment with the MoAb DB-1 starting 8 days after arthritis induction caused only slight and short-lived inhibitory effects. IFN-gamma appears to be a critical lymphokine for the development of adjuvant arthritis.
Wiesenberg
I
I
Department of Inflammation/Bone/Allergy, Pharmaceuticals Research Division, Ciba-Geigy, Basle, Switzerland.
Van der Meide
P H
PH
Schellekens
H
H
Alkan
S
S
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001169:Arthritis, Experimental / Q000209:etiology* / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D005620:Freund's Adjuvant / Q000008:administration & dosage; D007371:Interferon-gamma / Q000037:antagonists & inhibitors* / Q000276:immunology; D008297:Male; D051381:Rats; D011917:Rats, Inbred Lew
D000911:Antibodies, Monoclonal; D007371:Interferon-gamma; D005620:Freund's Adjuvant